Chinese drug Loberamisal extends stroke treatment window from 6 hours to 2 days
Chinese medical scientists have shattered the brief window of time available to limit stroke damage, effectively shielding injured brain cells and dramatically improving the odds of a full recovery. Brain cells start dying within minutes of a clot blocking an artery, leading to facial droop, affected speech and in severe cases, paralysis or death. Emergency treatments, such as clot-busting drugs…
Chinese researchers have developed a drug, Loberamisal, that extends the treatment window for stroke from six hours to 48 hours. This breakthrough was demonstrated in a large-scale clinical trial published in the Journal of the American Medical Association on September 10. The study found that 70% of patients who received Loberamisal intravenously within two days of a stroke regained complete functional independence, compared to a 57% recovery rate for those who received standard care.
The neuroprotective drug works by reducing brain cell excitability and blocking neuroinflammation and oxidative stress, thereby saving more injured brain cells. If confirmed by subsequent studies, this advancement could significantly improve stroke recovery rates worldwide, where an estimated 12 million new cases occur annually.
Brief written by urgent.news from South China Morning Post's own syndicated text. Machine-written — may contain errors; check the original before relying on it.
